<p>凤凰金融有限公司在最近向证券交易委员会的披露中表示，在第四季度将其在艾伯维公司（NYSE:ABBV - 免费报告）股票中的持股比例增加了 26.1%。该机构投资者在此期间额外购买了 8,047 股后，持有该公司 38,852 股股票。根据其最近向证券交易委员会的备案，凤凰金融有限公司在艾伯维的持股价值为 8,876,000 美元。</p>
<ul>
<li>这三大制药公司财报中最重要的部分并不是超出预期的业绩</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也增加或减少了在 ABBV 的持股。切尔西顾问公司在第三季度购买了艾伯维的新股份，价值约 26,000 美元。Westend 资本管理公司在第四季度收购了艾伯维的新头寸，价值 29,000 美元。德克萨斯资本银行在第三季度收购了艾伯维的新头寸，价值 31,000 美元。Legacy Wealth Management LLC 在第四季度将其在艾伯维的持股比例提高了 115.9%。Legacy Wealth Management LLC 现在持有该公司 136 股股票，价值 31,000 美元，此前在上个季度又购买了 73 股。最后，WestEnd Advisors LLC 在第四季度将其在艾伯维的持股增加了 160.4%。WestEnd Advisors LLC 现在持有 138 股该公司股票，价值 32,000 美元，此前在上个季度又购买了 85 股。目前，70.23% 的股票由机构投资者和对冲基金持有。</p>
<h2>艾伯维的内部交易</h2>
<p>在相关消息中，执行副总裁佩里·C·西亚蒂斯于 2 月 25 日星期三出售了 22,381 股公司的股票。股票以 230.00 美元的平均价格出售，总交易额为 5,147,630.00 美元。出售后，该执行副总裁在公司持有 38,137 股，价值约 8,771,510 美元。这笔交易代表了他们持股比例的 36.98% 的减少。该交易在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，高级副总裁大卫·瑞安·普渡于 3 月 4 日星期三出售了 5,230 股艾伯维股票。股票以 233.56 美元的平均价格出售，总交易额为 1,221,518.80 美元。交易完成后，该高级副总裁直接持有 2,654 股公司的股票，价值 619,868.24 美元。这笔交易使他们的持股比例减少了 66.34%。有关此交易的更多细节可在官方 SEC 披露中找到。内部人士持有公司 0.06% 的股票。</p>
<h2>艾伯维股票上涨 1.2%</h2>
<ul>
<li>MarketBeat 周报 – 04/27 - 05/01</li>
</ul>
<p>艾伯维（NYSE:ABBV）周五开盘价为 210.95 美元。艾伯维公司的 52 周低点为 176.57 美元，52 周高点为 244.81 美元。该公司的 50 日移动平均线为 210.78 美元，200 日移动平均线为 220.17 美元。该股票的市值为 3727.1 亿美元，市盈率为 103.92，市盈增长比率为 0.72，贝塔值为 0.32。</p>
<p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 4 月 29 日星期三发布了季度财报。公司报告本季度每股收益为 2.65 美元，超出分析师一致预期的 2.59 美元，超出幅度为 0.06 美元。该公司本季度的收入为 150 亿美元，而分析师预期为 147.2 亿美元。艾伯维的股本回报率为负的 576.45%，净利润率为 5.79%。去年同期，该公司每股收益为 2.46 美元。与去年同期相比，该公司的季度收入增长了 12.4%。整体来看，分析师预计艾伯维公司今年将发布 14.32 美元的每股收益。</p>
<h2>艾伯维宣布分红</h2>
<ul>
<li>艾伯维发出健康的趋势跟随信号：反弹即将到来吗？</li>
</ul>
<p>该公司最近还宣布了一项季度分红，将于 5 月 15 日星期五支付。4 月 15 日星期三的股东将获得每股 1.73 美元的分红。除息日期为 4 月 15 日星期三。这相当于年化分红为 6.92 美元，分红收益率为 3.3%。艾伯维的派息比率为 340.89%。</p>
<h2>华尔街分析师的看法</h2>
<p>一些研究分析师最近对 ABBV 股票发表了看法。派珀·桑德勒在周四的研究报告中将艾伯维的目标股价从 294.00 美元上调至 298.00 美元，并给予公司 “超配” 评级。巴克莱在 2 月 19 日星期四的研究报告中开始覆盖艾伯维股票。他们给予 “超配” 评级，并设定 275.00 美元的目标股价。DZ 银行在 4 月 30 日星期四的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。韦斯评级在 1 月 21 日星期三的报告中重申了对艾伯维的 “持有（c）” 评级。最后，加拿大皇家银行在 2 月 24 日星期二的报告中开始覆盖艾伯维股票。他们给予 “跑赢大盘” 评级，并设定 260.00 美元的目标股价。三位投资分析师对该股票给予 “强力买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 253.10 美元。</p>
<p><strong>查看我们最新的艾伯维股票报告</strong></p>
<h2>艾伯维简介</h2>
<p>（免费报告）</p>
<p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
<p>艾伯维的产品组合和研发管线涵盖多个主要治疗领域，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
<p><strong>想看看其他对 ABBV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
<p>在考虑艾伯维之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而艾伯维并不在名单上。</p>
<p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

艾伯维

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

<p>凤凰金融有限公司在第四季度将其在艾伯维（NYSE:ABBV）的持股增加了 26.1%，目前持有 38,852 股，价值 888 万美元。其他机构投资者也调整了他们的持股。艾伯维报告的季度每股收益为 2.65 美元，超出预期，并宣布每股派息 1.73 美元。分析师们提高了对艾伯维的目标股价，Piper Sandler 将其设定为 298.00 美元</p>

<p>Phoenix Financial Ltd. increased its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 26.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 38,852 shares of the company's stock after buying an additional 8,047 shares during the period. Phoenix Financial Ltd.'s holdings in AbbVie were worth $8,876,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>凤凰金融有限公司在最近向证券交易委员会的披露中表示，在第四季度将其在艾伯维公司（NYSE:ABBV - 免费报告）股票中的持股比例增加了 26.1%。该机构投资者在此期间额外购买了 8,047 股后，持有该公司 38,852 股股票。根据其最近向证券交易委员会的备案，凤凰金融有限公司在艾伯维的持股价值为 8,876,000 美元。</p>
</div><ul>
<li>The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>这三大制药公司财报中最重要的部分并不是超出预期的业绩</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie during the third quarter worth $31,000. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC grew its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也增加或减少了在 ABBV 的持股。切尔西顾问公司在第三季度购买了艾伯维的新股份，价值约 26,000 美元。Westend 资本管理公司在第四季度收购了艾伯维的新头寸，价值 29,000 美元。德克萨斯资本银行在第三季度收购了艾伯维的新头寸，价值 31,000 美元。Legacy Wealth Management LLC 在第四季度将其在艾伯维的持股比例提高了 115.9%。Legacy Wealth Management LLC 现在持有该公司 136 股股票，价值 31,000 美元，此前在上个季度又购买了 73 股。最后，WestEnd Advisors LLC 在第四季度将其在艾伯维的持股增加了 160.4%。WestEnd Advisors LLC 现在持有 138 股该公司股票，价值 32,000 美元，此前在上个季度又购买了 85 股。目前，70.23% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Transactions at AbbVie</h2>
<div class="lb-trans"><h2>艾伯维的内部交易</h2>
</div><p>In related news, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁佩里·C·西亚蒂斯于 2 月 25 日星期三出售了 22,381 股公司的股票。股票以 230.00 美元的平均价格出售，总交易额为 5,147,630.00 美元。出售后，该执行副总裁在公司持有 38,137 股，价值约 8,771,510 美元。这笔交易代表了他们持股比例的 36.98% 的减少。该交易在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，高级副总裁大卫·瑞安·普渡于 3 月 4 日星期三出售了 5,230 股艾伯维股票。股票以 233.56 美元的平均价格出售，总交易额为 1,221,518.80 美元。交易完成后，该高级副总裁直接持有 2,654 股公司的股票，价值 619,868.24 美元。这笔交易使他们的持股比例减少了 66.34%。有关此交易的更多细节可在官方 SEC 披露中找到。内部人士持有公司 0.06% 的股票。</p>
</div><h2>AbbVie Stock Up 1.2%</h2>
<div class="lb-trans"><h2>艾伯维股票上涨 1.2%</h2>
</div><ul>
<li>MarketBeat Week in Review – 04/27 - 05/01</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 04/27 - 05/01</li>
</ul>
</div><p>NYSE ABBV opened at $210.95 on Friday. AbbVie Inc. has a fifty-two week low of $176.57 and a fifty-two week high of $244.81. The business has a fifty day moving average of $210.78 and a 200-day moving average of $220.17. The stock has a market cap of $372.71 billion, a price-to-earnings ratio of 103.92, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV）周五开盘价为 210.95 美元。艾伯维公司的 52 周低点为 176.57 美元，52 周高点为 244.81 美元。该公司的 50 日移动平均线为 210.78 美元，200 日移动平均线为 220.17 美元。该股票的市值为 3727.1 亿美元，市盈率为 103.92，市盈增长比率为 0.72，贝塔值为 0.32。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.During the same quarter last year, the company earned $2.46 earnings per share. The business's revenue for the quarter was up 12.4% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 14.32 EPS for the current year.</p>
<div class="lb-trans"><p>艾伯维（NYSE:ABBV - 获取免费报告）最近于 4 月 29 日星期三发布了季度财报。公司报告本季度每股收益为 2.65 美元，超出分析师一致预期的 2.59 美元，超出幅度为 0.06 美元。该公司本季度的收入为 150 亿美元，而分析师预期为 147.2 亿美元。艾伯维的股本回报率为负的 576.45%，净利润率为 5.79%。去年同期，该公司每股收益为 2.46 美元。与去年同期相比，该公司的季度收入增长了 12.4%。整体来看，分析师预计艾伯维公司今年将发布 14.32 美元的每股收益。</p>
</div><h2>AbbVie Announces Dividend</h2>
<div class="lb-trans"><h2>艾伯维宣布分红</h2>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>艾伯维发出健康的趋势跟随信号：反弹即将到来吗？</li>
</ul>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie's payout ratio is 340.89%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 5 月 15 日星期五支付。4 月 15 日星期三的股东将获得每股 1.73 美元的分红。除息日期为 4 月 15 日星期三。这相当于年化分红为 6.92 美元，分红收益率为 3.3%。艾伯维的派息比率为 340.89%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of research analysts have recently weighed in on ABBV shares. Piper Sandler raised their price target on AbbVie from $294.00 to $298.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday. Barclays started coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an &#34;overweight&#34; rating and a $275.00 price objective on the stock. DZ Bank raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, April 30th. Weiss Ratings restated a &#34;hold (c)&#34; rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an &#34;outperform&#34; rating and a $260.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $253.10.</p>
<div class="lb-trans"><p>一些研究分析师最近对 ABBV 股票发表了看法。派珀·桑德勒在周四的研究报告中将艾伯维的目标股价从 294.00 美元上调至 298.00 美元，并给予公司 “超配” 评级。巴克莱在 2 月 19 日星期四的研究报告中开始覆盖艾伯维股票。他们给予 “超配” 评级，并设定 275.00 美元的目标股价。DZ 银行在 4 月 30 日星期四的研究报告中将艾伯维的评级从 “持有” 上调至 “强力买入”。韦斯评级在 1 月 21 日星期三的报告中重申了对艾伯维的 “持有（c）” 评级。最后，加拿大皇家银行在 2 月 24 日星期二的报告中开始覆盖艾伯维股票。他们给予 “跑赢大盘” 评级，并设定 260.00 美元的目标股价。三位投资分析师对该股票给予 “强力买入” 评级，十六位给予 “买入” 评级，六位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 253.10 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on ABBV</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的艾伯维股票报告</strong></p>
</div><h2>AbbVie Profile</h2>
<div class="lb-trans"><h2>艾伯维简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.</p>
<div class="lb-trans"><p>艾伯维是一家全球性的、以研究为驱动的生物制药公司，于 2013 年从雅培实验室分拆而成，总部位于伊利诺伊州北芝加哥。该公司专注于发现、开发和商业化针对复杂且常常是慢性医疗条件的治疗方案。其业务涵盖研究与开发、制造、监管事务和商业化，重点是将专业药物推向多个治疗领域的市场。</p>
</div><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p>
<div class="lb-trans"><p>艾伯维的产品组合和研发管线涵盖多个主要治疗领域，包括免疫学、肿瘤学、神经科学、病毒学和女性健康。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票</li>
<li>YETI 在财报超预期和上调前景后反弹</li>
<li>三家领先的量子公司在第一季度财报后的对比</li>
<li>思科的垂直反弹可能仍处于早期阶段</li>
<li>亚马逊与阿里巴巴：现在显然更具价值的选择</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABBV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ABBV 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取艾伯维公司（NYSE:ABBV - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在艾伯维吗？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑艾伯维之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而艾伯维并不在名单上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然艾伯维目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AbbVie Inc. $ABBV Shares Purchased by Phoenix Financial Ltd.

Market Beat

基因改革 ETF - ARK

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普全球医疗股指数 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

德州资本银行

Piper Sandler Cos

巴克莱银行

凤凰金融有限公司购买了艾伯维公司 $ABBV 的股票